Novartis is continuing a streak of pipeline ... and a licensing deal with China’s Shanghai Argo Biopharmaceutical covering two RNAi interference (RNAi) therapies in the cardiovascular and ...

Novartis also announced another agreement as JPM got underway, namely a licensing deal with China’s Shanghai Argo Biopharmaceutical covering two RNAi interference (RNAi) therapies in the ...

The pharma is spending $2.5 billion on an R&D center in Beijing. Elsewhere, Adaptimmune warned it could run out of cash and Pfizer sold its remaining stake in Haleon.

Novartis expects to submit 50 new drug applications in China by 2023, which will be split roughly evenly between innovative and off-patent drugs, the company’s head of global drug development ...

Tiered balconies of Novartis (Shanghai) Block - C6 (Shanghai, China, 2014) are reminiscent of towers representing many dynasties. Luyeyuan Stone Sculpture Art Museum (Chengdu, China, 2002 ...